BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 37321128)

  • 21. Viscum album L. extracts in breast and gynaecological cancers: a systematic review of clinical and preclinical research.
    Kienle GS; Glockmann A; Schink M; Kiene H
    J Exp Clin Cancer Res; 2009 Jun; 28(1):79. PubMed ID: 19519890
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Randomised and non-randomised prospective controlled cohort studies in matched-pair design for the long-term therapy of breast cancer patients with a mistletoe preparation (Iscador): a re-analysis.
    Grossarth-Maticek R; Ziegler R
    Eur J Med Res; 2006 Nov; 11(11):485-95. PubMed ID: 17182361
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cancer Patients' Experiences of Using Mistletoe (Viscum album): A Qualitative Systematic Review and Synthesis.
    Evans M; Bryant S; Huntley AL; Feder G
    J Altern Complement Med; 2016 Feb; 22(2):134-44. PubMed ID: 26684278
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mistletoe in conventional oncological practice: exemplary cases.
    Legnani W
    Integr Cancer Ther; 2008 Sep; 7(3):162-71. PubMed ID: 18956494
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of complementary treatment of breast cancer patients with standardized mistletoe extract during aftercare: a controlled multicenter comparative epidemiological cohort study.
    Beuth J; Schneider B; Schierholz JM
    Anticancer Res; 2008; 28(1B):523-7. PubMed ID: 18383896
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prospective controlled cohort studies on long-term therapy of ovairian cancer patients with mistletoe (Viscum album L.) extracts iscador.
    Grossarth-Maticek R; Ziegler R
    Arzneimittelforschung; 2007; 57(10):665-78. PubMed ID: 18074761
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Mistletoe (Viscum album) preparations: an optional drug for cancer patients?].
    Bar-Sela G; Gershony A; Haim N
    Harefuah; 2006 Jan; 145(1):42-6, 77. PubMed ID: 16450726
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Systematic analysis of mistletoe prescriptions in clinical studies.
    Staupe H; Buentzel J; Keinki C; Buentzel J; Huebner J
    J Cancer Res Clin Oncol; 2023 Aug; 149(9):5559-5571. PubMed ID: 36481925
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interaction of a standardized mistletoe (Viscum album) preparation with antitumor effects of Trastuzumab in vitro.
    Weissenstein U; Kunz M; Urech K; Regueiro U; Baumgartner S
    BMC Complement Altern Med; 2016 Aug; 16():271. PubMed ID: 27491866
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Problems of randomized studies in complementary medicine demonstrated in a study on mistletoe treatment of patients with breast cancer].
    Gerhard I; Abel U; Loewe-Mesch A; Huppmann S; Kuehn JJ
    Forsch Komplementarmed Klass Naturheilkd; 2004 Jun; 11(3):150-7. PubMed ID: 15249749
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preclinical and clinical effects of mistletoe against breast cancer.
    Marvibaigi M; Supriyanto E; Amini N; Abdul Majid FA; Jaganathan SK
    Biomed Res Int; 2014; 2014():785479. PubMed ID: 25136622
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety of high-dose intravenous mistletoe therapy in pediatric cancer patients: A case series.
    Zuzak TJ; Wasmuth A; Bernitzki S; Schwermer M; Längler A
    Complement Ther Med; 2018 Oct; 40():198-202. PubMed ID: 30219449
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antiproliferative potential from aqueous Viscum album L. preparations and their main constituents in comparison with ricin and purothionin on human cancer cells.
    Felenda JE; Turek C; Stintzing FC
    J Ethnopharmacol; 2019 May; 236():100-107. PubMed ID: 30840914
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical safety of combined therapy of immune checkpoint inhibitors and Viscum album L. therapy in patients with advanced or metastatic cancer.
    Thronicke A; Steele ML; Grah C; Matthes B; Schad F
    BMC Complement Altern Med; 2017 Dec; 17(1):534. PubMed ID: 29237435
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Introspective Patient Experience of Mistletoe Therapy in Cancer: A Qualitative Study.
    Mascher A; Pelzer F; Duncan LJ; Martin DD; Baumgartner S; Berger B
    Integr Cancer Ther; 2023; 22():15347354231198474. PubMed ID: 37731253
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Triterpenoids amplify anti-tumoral effects of mistletoe extracts on murine B16.f10 melanoma in vivo.
    Strüh CM; Jäger S; Kersten A; Schempp CM; Scheffler A; Martin SF
    PLoS One; 2013; 8(4):e62168. PubMed ID: 23614029
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of complementary mistletoe extract treatment on quality of life in breast, ovarian and non-small cell lung cancer patients. A prospective randomized controlled clinical trial.
    Piao BK; Wang YX; Xie GR; Mansmann U; Matthes H; Beuth J; Lin HS
    Anticancer Res; 2004; 24(1):303-9. PubMed ID: 15015612
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of Mistletoe Triterpene Acids on the Uptake of Mistletoe Lectin by Cultured Tumor Cells.
    Mulsow K; Enzlein T; Delebinski C; Jaeger S; Seifert G; Melzig MF
    PLoS One; 2016; 11(4):e0153825. PubMed ID: 27088729
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use and Safety of Viscum album L Applications in Cancer Patients With Preexisting Autoimmune Diseases: Findings From the Network Oncology Study.
    Oei SL; Thronicke A; Kröz M; Matthes H; Schad F
    Integr Cancer Ther; 2019; 18():1534735419832367. PubMed ID: 30808274
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mistletoe: for cancer or just for Christmas?
    de Giorgio A; Stebbing J
    Lancet Oncol; 2013 Dec; 14(13):1264-5. PubMed ID: 24275128
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.